Diffusion Pharmaceuticals Inc. (DFFN): Price and Financial Metrics

Diffusion Pharmaceuticals Inc. (DFFN)

Today's Latest Price: $1.22 USD

0.05 (-3.94%)

Updated Jan 27 8:53am

Add DFFN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

DFFN Stock Price Chart Interactive Chart >

Price chart for DFFN

DFFN Price/Volume Stats

Current price $1.22 52-week high $1.60
Prev. close $1.27 52-week low $0.25
Day low $1.22 Volume 86,857
Day high $1.22 Avg. volume 4,441,221
50-day MA $0.86 Dividend yield N/A
200-day MA $0.91 Market Cap 78.10M

Diffusion Pharmaceuticals Inc. (DFFN) Company Bio

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. The company is based in Charlottesville, Virginia.

DFFN Latest News Stream

Event/Time News Detail
Loading, please wait...

DFFN Latest Social Stream

Loading social stream, please wait...

View Full DFFN Social Stream

Latest DFFN News From Around the Web

Below are the latest news stories about Diffusion Pharmaceuticals Inc that investors may wish to consider to help them evaluate DFFN as an investment opportunity.

Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference

CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021. Conference specifics are as follows: Event:H.C. Wainwright BioConnect 2021 Conference Date: January 11-14, 2021 Registration:https://hcwevents.com/bioconnect/ The recorded presentation can be accessed by conference participants and the presentation deck can be accessed on the investor relations section of the Diffusion Pharmaceuticals’ website.About Diffusion Pharmaceuticals Inc. Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s abilit...

Yahoo | January 11, 2021

DFFN: Planning for Additional Studies of TSC…

By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Update on COVID-19 Trial Diffusion Pharmaceuticals (NASDAQ:DFFN) is currently conducting the 100-303 COVID trial of trans sodium crocetinate (TSC) in hospitalized COVID-19 patients in Romania ( NCT04573322 ). This is primarily a safety and tolerability study of TSC when it is administered four times a day for up to

Yahoo | December 4, 2020

Is Diffusion Pharmaceuticals Inc. (DFFN) A Good Stock To Buy?

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

Yahoo | November 30, 2020

Insider Buys Diffusion Pharmaceuticals Shares

Shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) rose by 4.1% from the previous closing price. A Form 4 filing filed with the SEC on …

Benzinga | November 18, 2020

Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates

Initiated and Advanced Clinical Trial Evaluating Lead Product Candidate in COVID-19 PatientsAnnounces Next Steps in Development Program for Lead Product CandidateEnded Quarter with $21.9 million in Cash and Cash EquivalentsCHARLOTTESVILLE, Va., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”) today reported financial results for the three and nine months ended September 30, 2020 and provided certain updates on its development program for its lead product candidate, trans sodium crocetinate (“TSC”), which is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions.Third quarter res...

Yahoo | November 12, 2020

Read More 'DFFN' Stories Here

DFFN Price Returns

1-mo 54.43%
3-mo 46.11%
6-mo 6.09%
1-year 185.51%
3-year -88.21%
5-year -99.34%
YTD 53.46%
2020 72.56%
2019 -76.85%
2018 -88.76%
2017 -47.79%
2016 -77.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8349 seconds.